|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - NovoCure Ltd (NVCR)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2019-01-16 Sale |
2019-01-18 4:19 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $45 | $900,060 | 124,743 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:17 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
25,000 | $45 | $1,125,075 | 37,500 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:15 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
200,000 | $45.16 | $9,031,704 | 271,164 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:13 pm |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
168,813 | $45.17 | $7,624,788 | 209,063 (Direct) |
View |
| 2019-01-16 Sale |
2019-01-18 4:12 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $45.15 | $677,250 | 181,547 (Direct) |
View |
| 2019-01-15 Sale |
2019-01-16 4:32 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $44.2 | $1,326,000 | 434,663 (Direct) |
View |
| 2019-01-14 Sale |
2019-01-16 4:31 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
200,000 | $43.51 | $8,701,200 | 346,863 (Direct) |
View |
| 2019-01-11 Sale |
2019-01-14 4:35 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
26,251 | $42 | $1,102,647 | 34,587 (Direct) |
View |
| 2019-01-10 Sale |
2019-01-14 4:34 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
54,930 | $40.88 | $2,245,810 | 201,488 (Direct) |
View |
| 2019-01-10 Sale |
2019-01-14 4:32 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $39.91 | $199,550 | 144,743 (Direct) |
View |
| 2019-01-10 Sale |
2019-01-14 4:30 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $42.35 | $1,270,500 | 464,663 (Direct) |
View |
| 2019-01-09 Sale |
2019-01-11 4:23 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $40 | $800,067 | 149,743 (Direct) |
View |
| 2019-01-09 Sale |
2019-01-11 4:21 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $40.15 | $602,250 | 196,547 (Direct) |
View |
| 2019-01-09 Sale |
2019-01-11 4:18 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
100,000 | $40 | $4,000,000 | 221,558 (Direct) |
View |
| 2019-01-09 Sale |
2019-01-11 4:16 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,988 | $40 | $359,550 | 26,075 (Direct) |
View |
| 2018-12-12 Sale |
2018-12-13 5:27 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
38,781 | $36 | $1,396,136 | 39,619 (Direct) |
View |
| 2017-12-10 Sale |
2018-12-12 4:26 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $33.49 | $167,450 | 169,743 (Direct) |
View |
| 2018-08-28 Sale |
2018-08-30 4:09 pm |
NovoCure Ltd | NVCR | Palti Yoram CTO |
4,334 | $40.27 | $174,549 | 1,041,054 (Indirect) |
View |
| 2018-08-24 Sale |
2018-08-28 4:24 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
35,547 | $40.01 | $1,422,173 | 47,397 (Direct) |
View |
| 2018-08-24 Sale |
2018-08-28 4:22 pm |
NovoCure Ltd | NVCR | Palti Yoram CTO |
25,666 | $40.03 | $1,027,308 | 1,058,838 (Indirect) |
View |
| 2018-08-22 Sale |
2018-08-24 4:05 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
31,179 | $37.67 | $1,174,603 | 72,671 (Direct) |
View |
| 2018-08-14 Sale |
2018-08-16 4:30 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
4,368 | $37.62 | $164,345 | 108,118 (Direct) |
View |
| 2018-08-02 Sale |
2018-08-06 4:15 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
7,126 | $35.01 | $249,499 | 110,008 (Direct) |
View |
| 2018-08-01 Sale |
2018-08-02 4:13 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
1,241 | $35.01 | $43,445 | 115,644 (Direct) |
View |
| 2018-07-27 Sale |
2018-07-30 4:39 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
62,727 | $35.08 | $2,200,335 | 175,602 (Direct) |
View |
| 2018-07-16 Sale |
2018-07-18 5:14 pm |
NovoCure Ltd | NVCR | Palti Yoram CTO |
30,000 | $0 | $0 | 1,098,739 (Indirect) |
View |
| 2018-07-02 Sale |
2018-07-05 4:08 pm |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
57,390 | $31.48 | $1,806,637 | 203,948 (Direct) |
View |
| 2018-06-27 Sale |
2018-06-29 4:05 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
70,364 | $32.09 | $2,257,699 | 69,318 (Direct) |
View |
| 2018-06-19 Sale |
2018-06-21 4:16 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
8,929 | $32.03 | $286,020 | 147,990 (Direct) |
View |
| 2018-06-18 Sale |
2018-06-19 4:14 pm |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
22,289 | $32 | $713,248 | 148,611 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-01-16 Exercise |
2019-01-18 4:19 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 124,743 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:19 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 124,743 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $11.85 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $19.25 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A 2027-05-02 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $11.85 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:17 pm |
N/A 2027-07-25 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
12,500 | $19.25 | 37,500 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:15 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 271,164 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
100,000 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
68,813 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
100,000 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:13 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
68,813 | $14.37 | 209,063 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 181,547 (Direct) |
View |
| 2019-01-16 Exercise |
2019-01-18 4:12 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 181,547 (Direct) |
View |
| 2019-01-15 Exercise |
2019-01-16 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 434,663 (Direct) |
View |
| 2019-01-15 Exercise |
2019-01-16 4:32 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 434,663 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-14 Exercise |
2019-01-16 4:31 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
100,000 | $3.44 | 346,863 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,751 | $14.37 | 34,587 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
17,500 | $11.46 | 34,587 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,751 | $14.37 | 34,587 (Direct) |
View |
| 2019-01-11 Exercise |
2019-01-14 4:35 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
17,500 | $11.46 | 34,587 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:34 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
54,930 | $14.37 | 201,488 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:34 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
54,930 | $14.37 | 201,488 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 144,743 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:32 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 144,743 (Direct) |
View |
| 2019-01-10 Option Award |
2019-01-14 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
25 | $27.2 | 464,663 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 464,663 (Direct) |
View |
| 2019-01-10 Exercise |
2019-01-14 4:30 pm |
N/A 2021-12-13 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
30,000 | $3.44 | 464,663 (Direct) |
View |
| 2019-01-10 Option Award |
2019-01-14 4:29 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
264 | $27.2 | 171,164 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 149,743 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:23 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
20,000 | $3.44 | 149,743 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 196,547 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:21 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
15,000 | $7.15 | 196,547 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
75,000 | $14.37 | 221,558 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
25,000 | $11.46 | 221,558 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:18 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
75,000 | $14.37 | 221,558 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:18 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
25,000 | $11.46 | 221,558 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,988 | $14.37 | 26,075 (Direct) |
View |
| 2019-01-09 Exercise |
2019-01-11 4:16 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
8,988 | $14.37 | 26,075 (Direct) |
View |
| 2018-12-12 Exercise |
2018-12-13 5:27 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
22,532 | $7.48 | 39,619 (Direct) |
View |
| 2018-12-12 Exercise |
2018-12-13 5:27 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,249 | $7.15 | 39,619 (Direct) |
View |
| 2018-12-12 Exercise |
2018-12-13 5:27 pm |
N/A 2024-02-25 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
22,532 | $7.48 | 39,619 (Direct) |
View |
| 2018-12-12 Exercise |
2018-12-13 5:27 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
16,249 | $7.15 | 39,619 (Direct) |
View |
| 2017-12-10 Exercise |
2018-12-12 4:26 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 169,743 (Direct) |
View |
| 2017-12-10 Exercise |
2018-12-12 4:26 pm |
N/A 2021-09-14 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
5,000 | $3.44 | 169,743 (Direct) |
View |
| 2018-08-02 Other |
2018-08-20 4:05 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
187,787 | $0 | 912,143 (Indirect) |
View |
| 2018-07-31 Option Award |
2018-08-02 4:17 pm |
N/A 2028-07-30 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
20,458 | $34 | 20,458 (Direct) |
View |
| 2018-07-31 Option Award |
2018-08-02 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
11,152 | $0 | 20,458 (Direct) |
View |
| 2018-07-31 Option Award |
2018-08-02 4:15 pm |
N/A 2028-07-30 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
37,101 | $34 | 37,101 (Direct) |
View |
| 2018-07-16 Exercise |
2018-07-18 4:54 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
2,330 | $3.59 | 914,473 (Direct) |
View |
| 2018-07-16 Exercise |
2018-07-18 4:54 pm |
N/A 2018-07-21 |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman |
2,330 | $3.59 | 914,473 (Direct) |
View |
| 2018-07-06 Option Award |
2018-07-10 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
1,231 | $17.25 | 5,231 (Direct) |
View |
| 2018-07-06 Option Award |
2018-07-10 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
1,231 | $17.25 | 21,305 (Direct) |
View |
| 2018-07-06 Option Award |
2018-07-10 4:11 pm |
N/A N/A |
NovoCure Ltd | NVCR | Kirson Eilon D. Chief Science Officer |
1,231 | $17.25 | 109,063 (Direct) |
View |
| 2018-07-06 Option Award |
2018-07-10 4:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO |
1,191 | $17.25 | 179,312 (Direct) |
View |
| 2018-07-06 Option Award |
2018-07-10 4:09 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf CEO |
795 | $17.25 | 70,113 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
27,825 | $7.03 | 203,948 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
29,565 | $7.48 | 203,948 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 4:08 pm |
N/A 2023-02-20 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
27,825 | $7.03 | 203,948 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 4:08 pm |
N/A 2024-02-26 |
NovoCure Ltd | NVCR | Ambrogi Michael J. COO |
29,565 | $7.48 | 203,948 (Direct) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Fri, 18 Jan 2019 16:21:45 -0600 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |